A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors such as pembrolizumab, ipilimumab, and nivolumab, now FDA-approved for use in treating several types of cancer, have been associated with immune-related adverse effects. Specifically, the antibodies targeting the programmed-cell death-1 immune checkpoint, pembrolizumab and nivolumab, have been rarely reported to induce the development of type 1 diabetes mellitus. Here we describe a case of a patient who developed antibody-positive type 1 diabetes mellitus following treatment with pembrolizumab in combination with systemic chemotherapy for metastatic adenocarcinoma of the lung. We will also provide a brief literature review of other rarely reported cases of type 1 diabetes presenting after treatment with pembrolizumab and nivolumab, as well as discussion regarding potential mechanisms of this adverse effect and its importance as these drugs continue to become even more widespread.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Newly developed autoimmune disease, such as type I diabetes in patients with no prior history of the disease, following checkpoint therapy has also been reported to occur”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [116]
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649
Genetic risk factors for type 1 diabetes
Pociot, F., & Lernmark, Å. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30582-7 · Cited by 553
Genetics of the HLA Region in the Prediction of Type 1 Diabetes
Noble, J. A., & Valdes, A. M. (2011) · Current Diabetes Reports · doi:10.1007/s11892-011-0223-x · Cited by 460
He, J., Hu, Y., Hu, M., & Li, B. (2015) · Scientific Reports · doi:10.1038/srep13110 · Cited by 401
CD28, CTLA‐4 and their ligands: who does what and to whom?
Sansom, D. M. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00121.x · Cited by 362
Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B., & Herold, K. C. (2015) · Diabetes Care · doi:10.2337/dc14-2349 · Cited by 347
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
“There have also been reports of patients experiencing exacerbation of pre-existing autoimmune conditions such as psoriasis (91, 92, 100) or developing new ones such as type 1 diabetes mellitus (101).”
BackgroundEndocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Hassel, J. C., Heinzerling, L., Aberle, J., Bähr, O., Eigentler, T. K., Grimm, M.-O., Grünwald, V., Leipe, J., Reinmuth, N., Tietze, J. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.003 · Cited by 331
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
de Filette, J. M. K., Pen, J. J., Decoster, L., Vissers, T., Bravenboer, B., Van der Auwera, B. J., Gorus, F. K., Roep, B. O., Aspeslagh, S., Neyns, B., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0291 · Cited by 275
“Additionally, the authors reviewed the reference lists of the included articles (4, 13-68) and identified 5 additional cases (69-72).”
BackgroundProgrammed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus
Clotman, K., Janssens, K., Specenier, P., Weets, I., & De Block, C. E. M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00728 · Cited by 232
Bajwa, R., Cheema, A., Khan, T., Amirpour, A., Paul, A., Chaughtai, S., Patel, S., Patel, T., Bramson, J., Gupta, V., et al. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3750 · Cited by 179
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Tan, M. H., Iyengar, R., Mizokami-Stout, K., Yentz, S., MacEachern, M. P., Shen, L. Y., Redman, B., & Gianchandani, R. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0073-4 · Cited by 172
Gauci, M.-L., Laly, P., Vidal-Trécan, T., Baroudjian, B., Gottlieb, J., Madjlessi-Ezra, N., Meda, L. D., Madelaine, I., Bagot, M., Basset‐Séguin, N., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2033-8 · Cited by 137
Stelmachowska‐Banaś, M., & Czajka-Oraniec, I. (2020) · Endocrine Connections · doi:10.1530/ec-20-0342 · Cited by 150
Godwin, J. L., Jaggi, S., Sirisena, I., Sharda, P., Rao, A. D., Mehra, R., & Veloski, C. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0245-2 · Cited by 128
First line Immunotherapy for Non-Small Cell Lung Cancer
Nasser, N. J., Gorenberg, M., & Agbarya, A. (2020) · Pharmaceuticals · doi:10.3390/ph13110373 · Cited by 86
“Immune-mediated side effects were reported and includes pneumonitis [34], colitis [35,36], hepatitis [37,38], adrenal insufficiency [39,40], hypophysitis [39], hyperthyroidism [41] and hypothyroidism [42,43], type 1 diabetes mellitus [44,45], and nephritis [46,47].”
BackgroundPreiato, V. L., Salvagni, S., Ricci, C., Ardizzoni, A., Pagotto, U., & Pelusi, C. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09618-w · Cited by 89
How we treat endocrine complications of immune checkpoint inhibitors
Paschou, S. Α., Stefanaki, K., Ψαλτοπούλου, Θ., Liontos, M., Koutsoukos, K., Zagouri, F., Lambrinoudaki, I. V., & Dimopoulos, M. A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100011 · Cited by 81
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
Iglesias, P. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.08.019 · Cited by 72
Kapke, J., Shaheen, Z., Kilari, D., Knudson, P., & Wong, S. (2017) · Case Reports in Oncology · doi:10.1159/000480634 · Cited by 69
Toxicity profiles of immunotherapy
Cousin, S., Sénéschal, J., & Italiano, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.005 · Cited by 64
Liu, Y., Zhang, H., Zhou, L., Li, W., Yang, L., Li, W., Li, K., & Liu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627612 · Cited by 65
“(33) 76 M NSCLC NR Pembrolizumab 3 Asymptomatic 34.”
BackgroundAlmawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
Inflammatory markers in autoimmunity induced by checkpoint inhibitors
Husain, B., Kirchberger, M. C., Erdmann, M., Schüpferling, S., Abolhassani, A.-R., Fröhlich, W., Berking, C., & Heinzerling, L. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03550-5 · Cited by 57
Sakurai, K., Niitsuma, S., Sato, R., Takahashi, K., & Arihara, Z. (2018) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.244.33 · Cited by 52
Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
Kyriacou, A., Melson, E., Chen, W., & Kempegowda, P. (2020) · Clinical Medicine · doi:10.7861/clinmed.2020-0054 · Cited by 49
Kottschade, L. A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0671-4 · Cited by 53
The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors
Marchand, L., Disse, E., Dalle, S., Reffet, S., Vouillarmet, J., Fabien, N., Thivolet, C. H., & Cugnet‐Anceau, C. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01402-w · Cited by 49
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
Wu, L., Tsang, V., Sasson, S. C., Menzies, A. M., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.764138 · Cited by 48
Shiba, M., Inaba, H., Ariyasu, H., Kawai, S., Inagaki, Y., Matsuno, S., Iwakura, H., Yamamoto, Y., Nishi, M., & Akamizu, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9518-17 · Cited by 42
“In the endocrine system, irAEs in the pituitary glands (3, 5), thyroid glands (6, 7), parathyroid glands (8), pancreas (3-5, 9-11), and adrenal glands (12) have been reported.”
BackgroundInfluentialAutoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
Cheema, A., Makadia, B., Karwadia, T., Bajwa, R., & Hossain, M. (2018) · World Journal of Oncology · doi:10.14740/wjon1085w · Cited by 41
“The six cases were reviewed and there salient points were compiled in Table 1 [6-11].”
BackgroundZezza, M., Kosinski, C., Mekoguem, C., Marino, L., Chtioui, H., Pitteloud, N., & Lamine, F. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0467-z · Cited by 46
Diabetes and blood glucose disorders under anti-PD1
Magis, Q., Gaudy-Marqueste, C., Basire, A., Loundou, A., Malissen, N., Troin, L., Monestier, S., Mallet, S., Hesse, S., Richard, M.-A., et al. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000218 · Cited by 39
Case Report: Pembrolizumab-Induced Type 1 Diabetes in a Patient with Metastatic Cholangiocarcinoma
Smith-Cohn, M., Gill, D. M., Voorhies, B. N., Agarwal, N., & Garrido‐Laguna, I. (2017) · Immunotherapy · doi:10.2217/imt-2017-0042 · Cited by 37
Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma
Tsiogka, A., Jansky, G. L., Bauer, J. W., & Koelblinger, P. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000384 · Cited by 37
Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors
Venetsanaki, V., Boutis, A. L., Chrisoulidou, A., & Papakotoulas, P. (2019) · Current Oncology · doi:10.3747/co.26.4151 · Cited by 41
Diabetes associated with immune checkpoint inhibition: presentation and management challenges
Galligan, A., Xu, W., Fourlanos, S., Nankervis, A. J., Chiang, C. Y., Mant, A. M., Parente, P., Rischin, D., Krishnamurthy, B., Sandhu, S. K., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13762 · Cited by 33
Current cancer therapies and their influence on glucose control
Yim, C., Mansell, K. D., Hussein, N., & Arnason, T. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.1010 · Cited by 36
Matsumura, K., Nagasawa, K., Ôshima, Y., Kikuno, S., Hayashi, K., Nishimura, A., Okubo, M., Uruga, H., Kishi, K., Kobayashi, T., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12679 · Cited by 32
Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis
Tzoulis, P., Corbett, R., Ponnampalam, S., Baker, E., Heaton, D., Doulgeraki, T., & Stebbing, J. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0111 · Cited by 34
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29
New onset diabetes after nivolumab treatment
Capitao, R., Bello, C., Fonseca, R., & Saraiva, C. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-220999 · Cited by 29
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
Liu, J., Shi, Y., Liu, X., Zhang, D., Zhang, H., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101473 · Cited by 30
The Future of Immunotherapy in the Treatment of Cancer
Kottschade, L. A. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.013 · Cited by 29
Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth
Shen, L., Li, J., Liu, Q., Das, M., Song, W., Zhang, X., Tiruthani, K., Dorosheva, O., Hu, H., Lai, S. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.039 · Cited by 33
Molecular adjuvants that modulate regulatory T cell function in vaccination: A critical appraisal
Batista-Duharte, A., Téllez-Martínez, D., Portuondo, D. L., & Carlos, I. Z. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.026 · Cited by 31
Multimodality imaging of endocrine immune related adverse events: a primer for radiologists
Alessandrino, F., Shah, H., & Ramaiya, N. H. (2018) · Clinical Imaging · doi:10.1016/j.clinimag.2017.12.014 · Cited by 27
Bedrose, S. S. D., Turin, C. G., Lavis, V. R., Kim, S. T., & Thosani, S. (2020) · AACE Clinical Case Reports · doi:10.4158/accr-2019-0234 · Cited by 27
“Despite the clinical benefits provided by this group of medications (1), important endocrine-related adverse effects have been described with these drugs such as primary and secondary hypothyroidism, thyroiditis, hypophysitis, primary and secondary adrenal insufficiency, and type 1 diabetes (2-5).”
BackgroundBrinkman, A. K. (2017) · Nursing Clinics of North America · doi:10.1016/j.cnur.2017.07.001 · Cited by 42
Immunotherapy in Metastatic Melanoma: A Novel Scenario of new Toxicities and their Management
Simeone, E., Grimaldi, A. M., Festino, L., Trojaniello, C., Vitale, M. G., Vanella, V., Palla, M., & Ascierto, P. A. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0005 · Cited by 28
“These AEs may appear at different times, usually from 1 week to 5 months after the start of the treatment [69].”
BackgroundA Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma
Sakaguchi, C., Ashida, K., Yano, S., Ohe, K., Wada, N. A., Hasuzawa, N., Matsuda, Y., Sakamoto, S., Sakamoto, R., Uchi, H., et al. (2019) · Current Oncology · doi:10.3747/co.26.4130 · Cited by 25
Leonardi, G. C., Oxnard, G. R., Haas, A. V., Lang, J. P., Williams, J. S., & Awad, M. M. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000173 · Cited by 24
Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
Zhang, A. L., Wang, F., Chang, L., McDonnell, M. E., & Min, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.620522 · Cited by 23
“The incidence of 25% of pancreatitis in our cohort suggests an increased risk of pancreatitis in patients who develop ICI-induced autoimmune diabetes (17).”
BackgroundYamamoto, N., Tsurutani, Y., Katsuragawa, S., Kubo, H., Sunouchi, T., Hirose, R., Hoshino, Y., Ichikawa, M., Takiguchi, T., Yukawa, H., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2780-19 · Cited by 23
“Table 3 summarizes previously published case reports on PD-1 inhibitor-related T1DM, including DKA and changes in the serum level of CPR (6-21).”
BackgroundNew-onset insulin-dependent diabetes due to nivolumab
Zaied, A. A., Aktürk, H. K., Joseph, R. W., & Lee, A. S. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0174 · Cited by 23
Matsuura, N., Koh, G., Konishi, C., Minamino, S., Takahara, Y., Harada, H., Kodama, K., & Emoto, M. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2203-3 · Cited by 22
Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer
Ni, R., Hu, Z., & Tao, R. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117430 · Cited by 23
Endocrine dysfunction following immune checkpoint inhibitor therapy
Konda, B., Nabhan, F. A., & Shah, M. H. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000357 · Cited by 21
Al‐Taie, A., & Sheta, N. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.10.016 · Cited by 20
Expert opinion on immunotherapy induced diabetes
Smati, S., Buffier, P., Bouillet, B., Archambeaud, F., Vergès, B. L., & Cariou, B. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.006 · Cited by 20
Farina, K., & Kane, M. P. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019850929 · Cited by 21
Martín, P., Blanco-Domínguez, R., & Sánchez‐Díaz, R. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00586-4 · Cited by 18
Lu, J., Ji, P., & French, S. W. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.09.019 · Cited by 20
Edahiro, R., Ishijima, M., Kurebe, H., Nishida, K., Uenami, T., Kanazu, M., Akazawa, Y., Yano, Y., & Mori, M. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13065 · Cited by 18
Alrifai, T., Ali, F. S., Saleem, S., Ruiz, D., Rifai, D., Younas, S., & Qureshi, F. M. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/8781347 · Cited by 19
The side effects of immune checkpoint inhibitor therapy on the endocrine system
Goyal, I., Pandey, M. R., Sharma, R. K., Chaudhuri, A., & Dandona, P. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_313_19 · Cited by 18
Fulminant type 1 diabetes mellitus associated with pembrolizumab
Mizab, C., Pérez, M. S., Rey, M. D. S., & García, M. H. (2017) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.01.005 · Cited by 14
Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
Si, X., Song, P., Ni, J., Di, M., He, C., Zhang, L., Liu, X., Li, Y., Wang, H., Guo, X., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13315 · Cited by 16
Zagouras, A. A., Patil, P. D., Yogi-Morren, D., & Pennell, N. A. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0806 · Cited by 13
“literature were in fact in individuals with previously described high risk haplotypes [5].”
BackgroundPembrolizumab use for the treatment of advanced melanoma
Specenier, P. M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1309388 · Cited by 14
Immune checkpoints inhibitors and hyperglycemia: A meta-analysis of randomized controlled trials
Monami, M., Naletto, L., Nreu, B., Dicembrini, I., Sesti, G., & Mannucci, E. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108115 · Cited by 12
A Case of Drug-Induced Severe Endocrinopathies
Villarreal, J., Townes, D. A., Vrablik, M. E., & Ro, K. A. (2018) · Advanced Emergency Nursing Journal · doi:10.1097/tme.0000000000000173 · Cited by 12
Diabetes fulminante secundaria a tratamiento con pembrolizumab
Mizab, C., Pérez, M. S., Rey, M. D. S., & García, M. H. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.01.005 · Cited by 12
Treating tumors with immune checkpoint inhibitors: Rationale and limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2017) · Trends in Immunotherapy · doi:10.24294/ti.v1.i1.20 · Cited by 20
Nivolumab-induced diabetes mellitus—a case report with literature review of the treatment options
Daetwyler, E., Zippelius, A., Danioth, S., Donath, M. Y., & Gut, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248919 · Cited by 10
Autoimmune diabetes from pembrolizumab: A case report and review of literature
Bhanderi, H., Khalid, F., Bodla, Z. H., Tayyeb, M., Du, D. T., & Meghal, T. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i11.535 · Cited by 12
Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review
Li, W., Wang, H., Chen, B., Zhao, S., Zhang, X., Jia, K., Deng, J., He, Y., & Zhou, C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.05 · Cited by 9
“However, a patient showed a slightly lower HbA1c after pembrolizumab treatment with a significantly increased blood glucose level (19).”
BackgroundAlpha-lipoic acid: A promising pharmacotherapy seen through the lens of kidney diseases
Dugbartey, G. J., Alornyo, K. K., Dapaa-Addo, C. O., Botchway, E., Kwashie, E. K., & Harley, Y. (2024) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2024.100206 · Cited by 10
Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab
Omodaka, T., Kiniwa, Y., Sato, Y., Suwa, M., Sato, M., Yamaguchi, T., Sato, A., Miyake, T., & Okuyama, R. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14331 · Cited by 8
Rapid onset type 1 diabetes associated with the programmed cell death‐1 inhibitor pembrolizumab
Boyle, V., Cundy, T., & Cutfield, R. G. (2019) · Internal Medicine Journal · doi:10.1111/imj.14340 · Cited by 8
Wen, Y., Xiao, H.-W., Yin, J.-H., Guo, H., Shan, M.-J., Shen, L., & Liu, L. (2022) · Medicine · doi:10.1097/md.0000000000032076 · Cited by 6
“[26–28] Some clinicians tried to use glucocorticoids to salvage β cells function but disappointingly, was unsuccessful, inversely, insulin resistance was seen in some patients.[29,30] Fortunately, our patient got a good clinical response both in CIP and hyperglycemia with corticosteroid and insulin therapy simultaneou…”
MethodGreene, A., Penner, S., Kunesh, J., Altaf, A. W., McGrade, W., & Niu, J. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241241493 · Cited by 6
Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice
Parthymos, I., Liamis, G. L., Dounousi, E. C., Pentheroudakis, G. E., Mauri, D., Zarkavelis, G., & Florentin, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102979 · Cited by 6
Nagy, S. S., Beckler, M. D., Hussein, A. M., & Kesselman, M. M. (2024) · Cureus · doi:10.7759/cureus.57894 · Cited by 6
Pembrolizumab: a case of drug‐induced autoimmune diabetes mellitus and colitis
Singh, N. R. (2018) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1436 · Cited by 5
Zhai, Y., Ye, X., Hu, F., Xu, J., Guo, X., Zhou, X., Zheng, Y., Zhao, X., Xu, X. G., Cao, Y., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.809063 · Cited by 5
“Indeed, several important adverse -4, Cytotoxic T-lymphocyte-associated rting system; FDA, Food and Drug p term; HLT, high-level term; IC, eckpoint inhibitors; irAEs, immuneDictionary for Regulatory Activities; ders; N, number of records; PD-1, grammed cell death-ligand 1; PT, io; SOC, system organ class; T1DM, n.org…”
BackgroundInfluentialPachpande, V., Mullangi, S., Lekkala, M. R., & Patel, A. (2022) · Cureus · doi:10.7759/cureus.24479 · Cited by 4
“A few cases have been reported of a new onset of type 1 DM and at least 1 case of worsening glycemic control in a pre-existing type 2 DM patient receiving immune checkpoint inhibitors [5-8].”
BackgroundDong, H., Li, S., Peng, Y., Zhang, X., Zheng, J., Xue, C., Zheng, Y., Yu, Y., Lu, X., Hu, Z., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.15023 · Cited by 4
Tay, W. L., Loh, W. J., & Kek, P. C. (2017) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2017.07.002 · Cited by 4
Lee, S., & Tse, G. (2021) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2021.0007 · Cited by 4
Gentzler, R. D., Mohindra, N. A., Jalal, S. I., Reckamp, K. L., Hall, R. D., Hanna, N. H., Chae, Y. K., Koczywas, M., Helenowski, I., & Patel, J. D. (2023) · The Oncologist · doi:10.1093/oncolo/oyad180 · Cited by 4
Self-citationFujiwara, N., Watanabe, M., Katayama, A., Noda, Y., Eguchi, J., Kataoka, H. U., Kagawa, S., & Wada, J. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4574 · Cited by 4
Jiang, Y., Xu, Z., Wu, Y., Li, X., Ling, J., Chen, Y., Zhu, Z., Yang, P., Liu, X., Zhang, D., et al. (2025) · Obesity Reviews · doi:10.1111/obr.13888 · Cited by 4
Unforeseen complications of pembrolizumab in breast reconstruction post-mastectomy
Aldarayseh, M., Sodhi, S. S., Musleh, G., Kumar, D., & Cholankeril, M. (2024) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2024_004675 · Cited by 2
“…include acute tubulointerstitial nephritis, arthritis, type-1 diabetes mellitus, encephalopathy, haemophagocytic histiocytosis, hepatotoxicity, non-ST-elevation myocardial infarction, necrotic myositis and scleroderma, in addition to autoimmune haemolytic anaemia and pancytopenia [4,5] .”
BackgroundPacichana, J. A., Osorio-Toro, L. M., Restrepo-Erazo, K., Ramos, A. F. G., Tafurt, G. P. R., & Liscano, Y. (2024) · Diabetology · doi:10.3390/diabetology5060043 · Cited by 2
“In this case, rapid intervention and appropriate management prevented further complications, reinforcing the importance of continuous glucose monitoring in patients receiving ICIs, a recommendation supported by other authors, including Chae et al., 2016 [27].”
Ji, P., Zhang, Y., Zhang, W., Leng, B., Nie, R., Shen, C., & Yu, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1499796 · Cited by 2
Sun, Y., Niu, H., Wang, Z., Wang, Y., Li, X., & Hao, J. (2021) · Materials Express · doi:10.1166/mex.2021.2022 · Cited by 2
Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma
Pavlick, A. C., & Weber, J. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_60 · Cited by 3
He, M., Zheng, Z., Guo, X., Cheng, G., Zhang, S., Liu, J., & Zhao, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1831879 · Cited by 2
Guo, J., Hu, Y., Liu, Y., & Wang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1947327 · Cited by 1
Cytostatic Agents: Monoclonal Antibodies Utilized in the Treatment of Solid Malignancies
Reeves, D. J. (2017) · Side effects of drugs annual · doi:10.1016/bs.seda.2017.06.027 · Cited by 2
Endocrine Toxicities of Immunotherapy
Pandey, M. R., Goyal, I., & Ernstoff, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00018-5 · Cited by 1
Diabetes mellitus geïnduceerd door immuuntherapie: een casus
Dekock, T., Taelman, T., Vanhaverbeke, G., Derijcke, S., & Ghysen, K. (2024) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.79.23.132 · Cited by 1
Metadata
- Authors
- Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F.
- Affiliations
- Northwestern University (US)
- University of Virginia (US)
- Corresponding author
- Chae, Young Kwang
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2016-10-19
- Volume
- 66
- Issue
- 1
- Pages
- 25-32
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11028603
- OpenAlex
- W2532961791
- Cited by
- 121
- References
- 34
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 15 · 2020: 16 · 2019: 18 · 2018: 18 · 2017: 20
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- pembrolizumab, type 1 diabetes, immune checkpoint inhibitors, immune-related adverse events, PD-1 inhibitors, nivolumab, ipilimumab, lung adenocarcinoma, metastatic cancer, systemic chemotherapy, autoimmune diabetes, drug-induced diabetes
- MeSH terms
- Aged, Antineoplastic Combined Chemotherapy Protocols, Diabetes Mellitus, Type 1, Humans, Lung Neoplasms, Male, Cell Cycle Checkpoints, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.